



NEOVACS lists on NYSE Alternext

Paris, 21 April 2010 – NYSE Euronext today announced the admission to NYSE Alternext of NEOVACS.

Biotechnology company NEOVACS is a leader in active immunotherapy with applications in autoimmune diseases, inflammatory conditions and cancer thanks to a new approach based on therapeutics called Kinoids®. NEOVACS' portfolio currently consists of three drug candidates: TNF α -K, IFN α -K and VEGF-K.

The admission of NEOVACS (mnemo: ALNEV) was by the listing of 8,424,600 existing shares making up its share capital and the issue of 2,084,636 new shares as part of a global offering¹. A further 2,346,605 new shares were created by the conversion of convertible bonds and exercise of equity warrants, setting the total amount raised at EUR 10,006,252.80.

The admission and issue price of NEOVACS shares was set at EUR 4.80 each. The company's capitalization on the day of admission amounted to EUR 61,708,036.80.

"We are delighted to welcome NEOVACS to NYSE Alternext for a listing that will accelerate the development of products in its portfolio," commented Ronald Kent, Group Executive Vice President and Head of International Listings at NYSE Euronext. *"NEOVACS will reap all the benefits of listing on NYSE Euronext, a reference in the industry, in a move enabling it to increase its equity and reinforce its reputation."*

Guy-Charles Fanneau de La Horie, CEO of NEOVACS, added: *"We are very pleased with our listing, and will be using the funds raised to pursue our existing strategy."*

The only Listing Sponsor is Invest Securities.

NYSE Alternext today counts 131 listed companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. They have raised over €2.27 billion altogether and their market capitalization totals €4.4 billion.

¹ A global offering consists of a public offering (open-price offering) and a global placement with institutional investors in France and abroad.

Press contacts:

NYSE Euronext (Paris): +33 (0)1 49 27 11 33

INVEST SECURITIES:

Jean-Emmanuel Vernay: +33(0)1 44 88 77 88- jevernay@invest-securities.com

About Neovacs

Neovacs is a biotechnology company focused on an active immunotherapy technology platform with applications in autoimmune diseases and other chronic conditions. It was founded as a spin-off from Pierre & Marie Curie University in Paris by Professor Daniel Zagury, MD, one of the world's leading immunologists.

Neovacs' portfolio currently consists of three drug candidates: TNF α -K, IFN α -K and VEGF-K. The company's lead immunotherapy program TNF α -K targets TNF α -mediated chronic inflammatory diseases. It is in a Phase I/II clinical trial in Crohn's Disease patients, and a Phase II trial in rheumatoid arthritis patients. This clinical study is also the focus of a collaboration with the diagnostics company BMD, with the goal of developing theranostic tools for personalized care. At the end of 2008, TNF α -K was selected by Thomson Reuters as the most promising drug to be entering Phase II clinical trials.

The company's second product candidate, IFN α K, an immunotherapy targeting interferon alpha (IFN α) in lupus patients, is entering Phase I/II for lupus.

The company's R&D has generated a broad patent estate.

For more information, visit the Neovacs web site at www.neovacs.com.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the S&P 100 index and Fortune 500. For more information, please visit: <http://www.nyx.com>.